KaloBios emerges from Chapter 11 bankruptcy
KaloBios announced it has emerged from Chapter 11 bankruptcy and has acquired the rights from Savant Neglected Diseases to develop benznidazole for treatment of Chagas disease. KaloBios made an upfront payment of $3 million and issued to Savant a warrant to purchase 200,000 shares of common stock. July 01, 2016